CellSource Co., Ltd. provided non-consolidated earnings guidance for the Fiscal Year Ending October 31, 2023. For the year, the company expects net sales of JPY 5,192 million, Operating profit of JPY 1,625 million, Profit of JPY 1,024 million or Basic EPS of JPY 54.81.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,190 JPY | +2.85% | -3.88% | -6.96% |
2023 | Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023. | CI |
2023 | MEDERI Inc. announced that it has received funding from CellSource Co., Ltd. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.96% | 147M | |
-21.70% | 8.05B | |
+77.60% | 4.56B | |
+8.47% | 2.74B | |
-2.80% | 2.65B | |
-49.62% | 2.02B | |
-13.10% | 1.8B | |
-20.79% | 1.46B | |
+16.24% | 1.2B | |
-44.65% | 1.13B |
- Stock Market
- Equities
- 4880 Stock
- News CellSource Co., Ltd.
- CellSource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023